family with sequence similarity 228 member BGenealiases: []
Q-omics provides the consensus-scored FAM228B profile across patient tissues and cancer cell-line models. FAM228B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM228B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, FAM228B RNA expression shows 20,395 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where FAM228B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM228B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM228B survival associations across molecular data types. FAM228B RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM228B RNA expression–survival associations across cancer types. High FAM228B expression shows unfavorable associations in ACC, LIHC, KICH, SCLC and BLCA, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM228B RNA expression.
This table summarizes FAM228B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM228B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM228B shows lower tumor expression in THCA, KICH, BLCA, UCEC and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher FAM228B RNA expression in tumor versus normal tissue (log2 FC = +0.433, t-test p < 0.001).
This table shows molecular features associated with FAM228B in patient tissues and cancer cell lines. In patient samples, FAM228B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM228B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_SCLC.
